| scholarly article | Q13442814 |
| P2093 | author name string | Frank J Gonzalez | |
| Ai-Ming Yu | |||
| Xi-Ling Jiang | |||
| P2860 | cites work | Role of CYP2E1 in the hepatotoxicity of acetaminophen | Q71142786 |
| Role of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2 | Q71690593 | ||
| Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein | Q73851378 | ||
| Loss of teratogenic response to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in mice lacking the Ah (dioxin) receptor | Q74032170 | ||
| Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir | Q79365640 | ||
| Conditional deletion of cytochrome P450 oxidoreductase in the liver and gastrointestinal tract: a new model for studying the functions of the P450 system | Q80160241 | ||
| The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib | Q81604961 | ||
| The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity | Q81605885 | ||
| Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse | Q81756811 | ||
| Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice | Q83150084 | ||
| Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man | Q93951315 | ||
| Knockout mice in xenobiotic metabolism | Q94335811 | ||
| The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity | Q24630723 | ||
| The organic solute transporter alpha-beta, Ostalpha-Ostbeta, is essential for intestinal bile acid transport and homeostasis | Q24651870 | ||
| Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators | Q24652367 | ||
| Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase | Q28191295 | ||
| Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR | Q28207193 | ||
| Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase | Q28210738 | ||
| Knock out, knock in, knock down--genetically manipulated mice and the Nobel Prize | Q28260920 | ||
| Transgenic mice with a hypomorphic NADPH-cytochrome P450 reductase gene: effects on development, reproduction, and microsomal cytochrome P450 | Q28278744 | ||
| Oral benzo[a]pyrene in Cyp1 knockout mouse lines: CYP1A1 important in detoxication, CYP1B1 metabolism required for immune damage independent of total-body burden and clearance rate | Q28288804 | ||
| Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas | Q28343187 | ||
| Spontaneous fetal loss caused by placental thrombosis in estrogen sulfotransferase-deficient mice | Q28507493 | ||
| Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development | Q28507862 | ||
| Toward the evaluation of function in genetic variability: characterizing human SNP frequencies and establishing BAC-transgenic mice carrying the human CYP1A1_CYP1A2 locus | Q28510807 | ||
| Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism | Q28510829 | ||
| Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3-deficient mice | Q28588462 | ||
| Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor | Q28589085 | ||
| Neonatal lethality associated with respiratory distress in mice lacking cytochrome P450 1A2 | Q28591646 | ||
| Developmental hyperbilirubinemia and CNS toxicity in mice humanized with the UDP glucuronosyltransferase 1 (UGT1) locus | Q30493784 | ||
| Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. | Q33185929 | ||
| Targeted disruption of the peptide transporter Pept2 gene in mice defines its physiological role in the kidney | Q33186727 | ||
| Use of transgenic mice in UDP-glucuronosyltransferase (UGT) studies | Q33596717 | ||
| Role of CYP2A5 in the clearance of nicotine and cotinine: insights from studies on a Cyp2a5-null mouse model | Q33613568 | ||
| A humanized UGT1 mouse model expressing the UGT1A1*28 allele for assessing drug clearance by UGT1A1-dependent glucuronidation | Q33861874 | ||
| Difference in desipramine metabolic profile between wild-type and CYP2D6-humanized mice | Q33887039 | ||
| Hepatocyte-specific mutation establishes retinoid X receptor alpha as a heterodimeric integrator of multiple physiological processes in the liver. | Q33964008 | ||
| Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene | Q33969200 | ||
| Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs | Q34059522 | ||
| Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis | Q34118792 | ||
| Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo | Q34156054 | ||
| The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. | Q45246954 | ||
| Differential hepatic effects of perfluorobutyrate mediated by mouse and human PPAR-alpha. | Q46054873 | ||
| Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin | Q46068650 | ||
| RXR alpha mutant mice establish a genetic basis for vitamin A signaling in heart morphogenesis. | Q46123728 | ||
| Tissue-specific, inducible, and hormonal control of the human UDP-glucuronosyltransferase-1 (UGT1) locus. | Q46140095 | ||
| Decreased renal organic anion secretion and plasma accumulation of endogenous organic anions in OAT1 knock-out mice. | Q46312451 | ||
| Potential role for human cytochrome P450 3A4 in estradiol homeostasis | Q46427703 | ||
| Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4. | Q46450153 | ||
| Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1). | Q46482976 | ||
| Utility of a novel Oatp1b2 knockout mouse model for evaluating the role of Oatp1b2 in the hepatic uptake of model compounds | Q46537962 | ||
| Theophylline pharmacokinetics: comparison of Cyp1a1(-/-) and Cyp1a2(-/-) knockout mice, humanized hCYP1A1_1A2 knock-in mice lacking either the mouse Cyp1a1 or Cyp1a2 gene, and Cyp1(+/+) wild-type mice. | Q46560571 | ||
| Generation and characterization of a transgenic mouse model with hepatic expression of human CYP2A6. | Q46673095 | ||
| Retinoid X receptor alpha Regulates the expression of glutathione s-transferase genes and modulates acetaminophen-glutathione conjugation in mouse liver | Q46699172 | ||
| Differential metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in mice humanized for CYP1A1 and CYP1A2. | Q46707333 | ||
| Generation of mice transgenic for human CYP2C18 and CYP2C19: characterization of the sexually dimorphic gene and enzyme expression | Q46752498 | ||
| Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. | Q46753745 | ||
| Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene | Q46775437 | ||
| Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice | Q46874554 | ||
| Characterization of mice lacking the multidrug resistance protein MRP2 (ABCC2). | Q46900104 | ||
| Impact of genetic knockout of PEPT2 on cefadroxil pharmacokinetics, renal tubular reabsorption, and brain penetration in mice | Q48192173 | ||
| Targeted disruption of the PEPT2 gene markedly reduces dipeptide uptake in choroid plexus. | Q48429282 | ||
| The PREgnane X receptor gene-humanized mouse: a model for investigating drug-drug interactions mediated by cytochromes P450 3A. | Q48645885 | ||
| Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. | Q51431176 | ||
| Growth hormone determines sexual dimorphism of hepatic cytochrome P450 3A4 expression in transgenic mice. | Q51832019 | ||
| Conditional knockout of the mouse NADPH-cytochrome p450 reductase gene. | Q52101444 | ||
| Genetic analysis of RXR alpha developmental function: convergence of RXR and RAR signaling pathways in heart and eye morphogenesis. | Q52214194 | ||
| Determination of the role of target tissue metabolism in lung carcinogenesis using conditional cytochrome P450 reductase-null mice. | Q53329946 | ||
| Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha. | Q53428750 | ||
| A Mouse Model with Liver-Specific Deletion and Global Suppression of the NADPH-Cytochrome P450 Reductase Gene: Characterization and Utility for in Vivo Studies of Cyclophosphamide Disposition | Q58483537 | ||
| Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. | Q34331552 | ||
| The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. | Q34388548 | ||
| Cytochrome P450 and xenobiotic receptor humanized mice | Q34545343 | ||
| Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis | Q34565215 | ||
| Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects | Q34713638 | ||
| Study of P450 function using gene knockout and transgenic mice | Q35015944 | ||
| Distinct response to dioxin in an arylhydrocarbon receptor (AHR)-humanized mouse | Q35021811 | ||
| Characterization of organic anion transporting polypeptide 1b2-null mice: essential role in hepatic uptake/toxicity of phalloidin and microcystin-LR. | Q35234128 | ||
| Role of gene knockout and transgenic mice in the study of xenobiotic metabolism | Q35620649 | ||
| Identification of novel roles of the cytochrome p450 system in early embryogenesis: effects on vasculogenesis and retinoic Acid homeostasis | Q35661189 | ||
| Transgenic analysis of human drug-metabolizing enzymes: preclinical drug development and toxicology | Q35679642 | ||
| Increased resistance to acetaminophen hepatotoxicity in mice lacking glutathione S-transferase Pi. | Q35823922 | ||
| Genetically modified mouse models for pharmacogenomic research | Q35889610 | ||
| Generation of 'humanized' hCYP1A1_1A2_Cyp1a1/1a2(-/-) mouse line | Q36014555 | ||
| Increased skin tumorigenesis in mice lacking pi class glutathione S-transferases | Q36068630 | ||
| Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism | Q36099442 | ||
| Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins | Q36108920 | ||
| Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations | Q36139458 | ||
| Animal models of xenobiotic receptors | Q36230604 | ||
| Mechanism of chloroform-induced renal toxicity: non-involvement of hepatic cytochrome P450-dependent metabolism | Q36508577 | ||
| Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes | Q36667359 | ||
| Evaluation of drug-transporter interactions using in vitro and in vivo models | Q36822902 | ||
| Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin | Q36926314 | ||
| Deletion of the NADPH-cytochrome P450 reductase gene in cardiomyocytes does not protect mice against doxorubicin-mediated acute cardiac toxicity | Q36953788 | ||
| Small interfering RNA in drug metabolism and transport | Q36990026 | ||
| An intestinal epithelium-specific cytochrome P450 (P450) reductase-knockout mouse model: direct evidence for a role of intestinal p450s in first-pass clearance of oral nifedipine | Q37104008 | ||
| Mice as clinically relevant models for the study of cytochrome P450-dependent metabolism | Q37128667 | ||
| Dynamic patterns of histone methylation are associated with ontogenic expression of the Cyp3a genes during mouse liver maturation | Q37168368 | ||
| Glutathione-S-transferase P protects against endothelial dysfunction induced by exposure to tobacco smoke. | Q37200254 | ||
| Regulation of human CYP2C18 and CYP2C19 in transgenic mice: influence of castration, testosterone, and growth hormone | Q37233832 | ||
| Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model | Q37309305 | ||
| Mrp4 confers resistance to topotecan and protects the brain from chemotherapy | Q37349714 | ||
| P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs | Q37355653 | ||
| Pharmacoepigenetics: its role in interindividual differences in drug response | Q37401062 | ||
| MicroRNAs regulate CYP3A4 expression via direct and indirect targeting | Q37402750 | ||
| Pharmacokinetic assessment of multiple ATP-binding cassette transporters: the power of combination knockout mice | Q37547727 | ||
| Role of microRNAs in the regulation of drug metabolism and disposition | Q37604383 | ||
| Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution | Q40105416 | ||
| The role of chrysin and the ah receptor in induction of the human UGT1A1 gene in vitro and in transgenic UGT1 mice | Q40178575 | ||
| Expression of the human UGT1 locus in transgenic mice by 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (WY-14643) and implications on drug metabolism through peroxisome proliferator-activated receptor alpha activation. | Q40199678 | ||
| Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion | Q40325508 | ||
| A traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor CAR. | Q40364666 | ||
| Analysis of the in vivo functions of Mrp3. | Q40438126 | ||
| The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. | Q40458879 | ||
| The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. | Q40626046 | ||
| The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. | Q40674439 | ||
| The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism | Q40845372 | ||
| Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione. | Q41077699 | ||
| Humanized xenobiotic response in mice expressing nuclear receptor SXR. | Q41753938 | ||
| Targeted knockout of Cyp1a1 gene does not alter hepatic constitutive expression of other genes in the mouse [Ah] battery | Q42481869 | ||
| Hepatic cytochrome P-450 reductase-null mice show reduced transcriptional response to quercetin and reveal physiological homeostasis between jejunum and liver. | Q42679593 | ||
| Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. | Q42930123 | ||
| Pinoline may be used as a probe for CYP2D6 activity | Q43026876 | ||
| Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam | Q43276891 | ||
| Targeted disruption of the mouse estrogen sulfotransferase gene reveals a role of estrogen metabolism in intracrine and paracrine estrogen regulation | Q43802380 | ||
| Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. | Q43993855 | ||
| In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. | Q44106452 | ||
| The relative contribution of monoamine oxidase and cytochrome p450 isozymes to the metabolic deamination of the trace amine tryptamine. | Q44285503 | ||
| Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. | Q44346889 | ||
| Expression of the Human CYP3A4 Gene in the Small Intestine of Transgenic Mice: In Vitro Metabolism and Pharmacokinetics of Midazolam | Q44403612 | ||
| Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase | Q44460548 | ||
| Severe cholestasis induced by cholic acid feeding in knockout mice of sister of P-glycoprotein | Q44675039 | ||
| A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification | Q44741483 | ||
| Retinoid X receptor alpha regulates glutathione homeostasis and xenobiotic detoxification processes in mouse liver | Q44772887 | ||
| Organic anion transport in choroid plexus from wild-type and organic anion transporter 3 (Slc22a8)-null mice | Q44838084 | ||
| Cyp1a1(-/-) male mice: protection against high-dose TCDD-induced lethality and wasting syndrome, and resistance to intrahepatocyte lipid accumulation and uroporphyria | Q44849475 | ||
| Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha | Q44917917 | ||
| Disruption of the ugt1 locus in mice resembles human Crigler-Najjar type I disease | Q44966651 | ||
| The cyp2e1-humanized transgenic mouse: role of cyp2e1 in acetaminophen hepatotoxicity | Q45171476 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 27-40 | |
| P577 | publication date | 2010-09-21 | |
| P1433 | published in | Drug Metabolism Reviews | Q5308857 |
| P1476 | title | Drug-metabolizing enzyme, transporter, and nuclear receptor genetically modified mouse models | |
| P478 | volume | 43 |
| Q38131587 | A mouse with humanized liver as an animal model for predicting drug effects and for studying hepatic viral infection: where to next? |
| Q38107993 | ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. |
| Q38307535 | Clinical pharmacokinetics and pharmacodynamics of clopidogrel |
| Q34293583 | Development and characterization of a novel mouse line humanized for the intestinal peptide transporter PEPT1 |
| Q93016097 | Effects of total parenteral nutrition on drug metabolism gene expression in mice |
| Q37991010 | Efflux transporters in the blood-brain interfaces--in vitro and in vivo methods and correlations |
| Q37207769 | Emerging applications of metabolomics in studying chemopreventive phytochemicals. |
| Q37948908 | Humanized transgenic mouse models for drug metabolism and pharmacokinetic research |
| Q51257526 | Investigating the substrate binding mechanism of sulfotransferase 2A1 based on substrate tunnel analysis: a molecular dynamics simulation study. |
| Q37855792 | Knockout and transgenic mice in glutathione transferase research |
| Q37654881 | LC-MS-based Metabolomics of Xenobiotic-induced Toxicities. |
| Q64074047 | Membrane transporter data to support kinetically-informed chemical risk assessment using non-animal methods: Scientific and regulatory perspectives |
| Q42495773 | New technologies in drug metabolism and toxicity screening: organ-to-organ interaction |
| Q35079542 | Nonlinear pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine in mice |
| Q38255685 | Novel pre-clinical methodologies for pharmacokinetic drug-drug interaction studies: spotlight on "humanized" animal models. |
| Q36776603 | Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status |
| Q46460825 | Species Differences in Human and Rodent PEPT2-Mediated Transport of Glycylsarcosine and Cefadroxil in Pichia Pastoris Transformants |
| Q49646816 | Sulfenylation of Human Liver and Kidney Microsomal Cytochromes P450 and Other Drug Metabolizing Enzymes as a Response to Redox Alteration. |
Search more.